ScreenerHero

INKT MiNK Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · minktherapeutics.com
11.42USD-2.39%Mkt Cap: 58.28M $P/E: —

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell ther…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap58.28M USD
Enterprise Value50.90M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-12.49M USD
Revenue/Share—
Last Price11.42 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees15
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.42
PEG—
EV/EBITDA-4.30
EV/Revenue—
P/S—
P/B-4.25
EPS (TTM)-2.29
EPS (Forward)-2.65
52W Range
8.48035% of range16.93
52W High16.93 USD
52W Low8.480 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE87.82%
ROA-87.75%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.93M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-9.18%
Net Debt-8.81M USD
Net Debt/EBITDA0.74
Balance Sheet
Debt/Equity-0.36
Current Ratio1.23
Quick Ratio1.16
Book Value/Sh-2.75 USD
Cash/Share1.73 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJan 28, 2025
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)39.00 USD
Upside (mean)+241.5%
Target Range35.00 USD – 43.00 USD
35.00+241.5% to mean43.00
# Analysts2
Ownership
Shares Out.5.10M
Float2.08M
Insiders59.37%
Institutions4.01%
Short Interest
Short Ratio4.1d
Short % Float2.24%
Short % Out.1.12%
Shares Short57.14K
Short (prev mo.)78.32K
Technical
SMA 5011.56 (-1.2%)
SMA 20011.42 (-0.0%)
Beta0.47
S&P 52W Chg16.45%
Avg Vol (30d)18.13K
Avg Vol (10d)24.41K
Technical Indicators
RSI (14)42.9
MACD0.1285
MACD Signal0.2249
MACD Hist.-0.0965
BB Upper12.80 USD
BB Middle12.08 USD
BB Lower11.36 USD
BB Width11.92%
ATR (14)0.6196 USD
Vol Ratio (20d)0.60x